Table 1.
Baseline characteristics of women diagnosed with atypical hyperplasia and lobular or ductal carcinoma in situ at Columbia University Medical Center, New York, NY (2007–2015)
| Characteristic | No Chemoprevention (n = 1214; 70.62%) |
Chemoprevention (n = 505; 29.38%) |
Total (n = 1719, %) |
p-value | ||||
|---|---|---|---|---|---|---|---|---|
| Breast Histology | Atypical Hyperplasia | 420 | (34.60) | 83 | (13.44) | 503 | (29.26) | |
| Lobular Carcinoma in situ | 294 | (24.22) | 107 | (21.19) | 401 | (23.33) | ||
| Ductal Carcinoma in situ | 500 | (41.19) | 315 | (62.38) | 815 | (47.41) | <.0001 | |
|
| ||||||||
| Age | Mean Age - Years [SD] | 60.11 | (12.61) | 60.48 | (9.95) | 60.22 | (11.88) | |
| <45 Years | 114 | (9.39) | 23 | (4.55) | 137 | (7.97) | ||
| 45–54 Years | 328 | (27.02) | 118 | (23.27) | 446 | (25.95) | ||
| 55–64 Years | 351 | (28.91) | 185 | (36.63) | 536 | (31.18) | ||
| 65–74 Years | 255 | (21.00) | 128 | (25.35) | 383 | (22.28) | ||
| 75+ | 166 | (13.67) | 51 | (10.10) | 217 | (12.62) | <.0001 | |
|
| ||||||||
| Menopause | No | 420 | (34.60) | 120 | (23.76) | 540 | (31.41) | |
| Yes | 794 | (65.40) | 385 | (76.24) | 1179 | (68.59) | <.0001 | |
|
| ||||||||
| Race and Ethnicity | Non-Hispanic White | 551 | (45.39) | 221 | (43.76) | 772 | (44.91) | |
| Non-Hispanic Black | 98 | (8.07) | 60 | (11.88) | 158 | (9.19) | ||
| Hispanic | 255 | (21.00) | 142 | (28.12) | 397 | (23.09) | ||
| Asian | 60 | (4.94) | 41 | (8.12) | 101 | (5.88) | ||
| Other | 250 | (20.59) | 41 | (8.12) | 291 | (16.93) | <.0001 | |
|
| ||||||||
| Body Mass Index [BMI] (kg/m2) | Mean BMI - Score [SD] | 27.06 | (6.16) | 28.05 | (6.20) | 27.39 | (6.19) | |
| <18.5 | 34 | (2.80) | 8 | (1.58) | 42 | (2.44) | ||
| 18.5–24.99 | 384 | (31.63) | 167 | (33.07) | 551 | (32.05) | ||
| 25–29.99 | 301 | (24.79) | 154 | (30.50) | 455 | (26.47) | ||
| 30+ | 264 | (21.75) | 162 | (32.08) | 426 | (24.78) | ||
| Unknown | 231 | (19.03) | 14 | (2.77) | 245 | (14.25) | <.0001 | |
|
| ||||||||
| Family History of Breast Cancer | No | 1120 | (92.60) | 368 | (72.87) | 1488 | (86.56) | |
| Yes | 94 | (7.74) | 137 | (27.13) | 231 | (13.44) | <.0001 | |
|
| ||||||||
| Hysterectomy | No | 1183 | (97.45) | 491 | (97.23) | 1674 | (97.38) | |
| Yes | 31 | (2.55) | 14 | (2.77) | 45 | (2.62) | 0.7959 | |
|
| ||||||||
| Comorbiditiesa | No | 1177 | (96.95) | 494 | (97.82) | 1671 | (97.21) | |
| DVT/PE/Stroke | 30 | (2.47) | 8 | (1.58) | 38 | (2.21) | ||
| Uterine Cancer | 7 | (0.58) | 3 | (0.59) | 10 | (0.58) | 0.5223 | |
|
| ||||||||
| HRT Useb | No | 1204 | (99.18) | 466 | (92.28) | 1670 | (97.15) | |
| Yes | 10 | (0.82) | 39 | (7.72) | 49 | (2.85) | <.0001 | |
|
| ||||||||
| Medical Oncology Referral | No | 1028 | (84.68) | 126 | (24.95) | 1154 | (67.13) | |
| Yes | 186 | (15.32) | 379 | (75.05) | 565 | (32.87) | <.0001 | |
a
DVT = Deep Vein Thrombosis, PE = Pulmonary Embolism
b
HRT = Hormone Replacement Therapy